Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Editas Medicine Inc (NASDAQ: EDIT) was $2.41 for the day, up 0.42% from the previous closing price of $2.4. In other words, the price has increased by $0.42 from its previous closing price. On the day, 1.01 million shares were traded. EDIT stock price reached its highest trading level at $2.41 during the session, while it also had its lowest trading level at $2.34.
Ratios:
Our analysis of EDIT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.86 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 5.85 whereas as Long-Term Debt/Eq ratio is at 5.03.
Upgrades & Downgrades
In the most recent recommendation for this company, H.C. Wainwright on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 03 ’25 when Burkly Linda sold 710 shares for $2.60 per share. The transaction valued at 1,843 led to the insider holds 69,490 shares of the business.
Parison Amy sold 458 shares of EDIT for $1,189 on Sep 03 ’25. The SVP, Chief Financial Officer now owns 16,369 shares after completing the transaction at $2.60 per share. On Sep 03 ’25, another insider, O’Neill Gilmore Neil, who serves as the CEO of the company, sold 5,592 shares for $2.60 each. As a result, the insider received 14,517 and left with 274,690 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EDIT now has a Market Capitalization of 235260976 and an Enterprise Value of 89264968. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.07 while its Price-to-Book (P/B) ratio in mrq is 16.71. Its current Enterprise Value per Revenue stands at 1.925 whereas that against EBITDA is -0.797.
Stock Price History:
The Beta on a monthly basis for EDIT is 2.45, which has changed by 0.100456595 over the last 52 weeks, in comparison to a change of 0.1326145 over the same period for the S&P500. Over the past 52 weeks, EDIT has reached a high of $4.54, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is -24.34%, while the 200-Day Moving Average is calculated to be 3.53%.
Shares Statistics:
EDIT traded an average of 2.41M shares per day over the past three months and 1394140 shares per day over the past ten days. A total of 97.62M shares are outstanding, with a floating share count of 97.07M. Insiders hold about 0.57% of the company’s shares, while institutions hold 45.42% stake in the company. Shares short for EDIT as of 1763078400 were 10005943 with a Short Ratio of 4.14, compared to 1760486400 on 7619416. Therefore, it implies a Short% of Shares Outstanding of 10005943 and a Short% of Float of 10.27.
Earnings Estimates
. The current market rating for Editas Medicine Inc (EDIT) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.32 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.63 and -$2.13 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.06, with 8.0 analysts recommending between -$0.62 and -$1.41.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 12 analysts. It ranges from a high estimate of $40.5M to a low estimate of $500k. As of . The current estimate, Editas Medicine Inc’s year-ago sales were $30.6MFor the next quarter, 12 analysts are estimating revenue of $1.38M. There is a high estimate of $3.77M for the next quarter, whereas the lowest estimate is $500k.
A total of 13 analysts have provided revenue estimates for EDIT’s current fiscal year. The highest revenue estimate was $56.28M, while the lowest revenue estimate was $16.3M, resulting in an average revenue estimate of $23.63M. In the same quarter a year ago, actual revenue was $32.31MBased on 13 analysts’ estimates, the company’s revenue will be $16.65M in the next fiscal year. The high estimate is $41M and the low estimate is $2M.
